Prospects and Challenges of Developing Plant‐Derived Snake Antivenin Natural Products: A Focus on West Africa

Snakebite envenomation (SBE) is an important public health issue that is now receiving renewed attention following its reclassification as a Neglected Tropical Disease (NTD). Most incidences occur in rural areas of resource‐limited countries, as such, timely and appropriate medical care for SBE is often inaccessible. The administration of anti‐snake venom serum (ASV) is the only effective definitive treatment of SBE, but treatment failure to available ASVs is not uncommon. Emerging evidence highlights the potential of small‐molecule compounds as inhibitors against toxins of snake venom. This presents an encouraging prospect to develop an alternative therapeutic option for the treatment SBE, that may be amenable for use at the point of care in resource‐constraint settings. In view of the pivotal role of natural products in modern drug discovery programmes, there is considerable interest in ethno‐pharmacological mining of medicinal plants and plant‐derived medicinal compounds toward developing novel snake venom‐neutralising therapeutics. In this review, we compile a collection of medicinal plants used in the treatment of SBE in West Africa and highlight their promise as potential botanical drugs or as sources of novel small‐molecule compounds for the treatment of SBE. The challenges that must be surmounted to bring this to fruition including the need for (sub) regional collaboration have been discussed. Snakebite envenomation (SBE) is a serious health burden in many developing countries. Alternative therapeutics are urgently needed to address the many limitations of current snake antivenom‐based treatment. Small‐molecule inhibitors of venom toxins are emerging as promising candidates. This Review examines the prospects of identifying novel plant‐derived toxins inhibitors using ethnopharmacological exploration of rich and diverse library of plants, with particular emphasis on West Africa.